Article

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of…

medRxiv · 2023 · Brunet, L.; Alexandre, D.; Lee, J.; Blanquer-Rossello, M. d. M.; Guernet, A.; Chhouri, H.; Kherrouche, Z.; Arabo, A.; Yao, S.; Godefroy, D.; Dehedin, J.; Li, J.-R.; Duparc, C.; Jamme, P.; Vinchent, A.; Berard, C.; Tulasne, D.; Arena, S.; Bardelli, A.; Cheng, C.; Cho, B. C.; Coulouarn, C.; Aaronson, S.; Cortot, A. B.; Anouar, Y.; Grumolato, L.

Key facts

Title Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
First author Brunet, L.; Alexandre, D.; Lee, J.; Blanquer-Rossello, M. d. M.; Guernet, A.; Chhouri, H.; Kherrouche, Z.; Arabo, A.; Yao, S.; Godefroy, D.; Dehedin, J.; Li, J.-R.; Duparc, C.; Jamme, P.; Vinchent, A.; Berard, C.; Tulasne, D.; Arena, S.; Bardelli, A.; Cheng, C.; Cho, B. C.; Coulouarn, C.; Aaronson, S.; Cortot, A. B.; Anouar, Y.; Grumolato, L.
Journal medRxiv
Published Jun 22, 2023
DOI 10.1101/2023.06.19.545595
Devices mentioned BK110039, K010696, K042884, K123955, K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183 and 5 more
Product codes mentioned GIA, JJQ, KIT, KPA, MVU, MYA, MXZ, NDS, NJT, NKF, NQF, OOI and 3 more

At a glance

  • 10–99 FDA submissions mentioned
  • 10–99 Product codes mentioned

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About Literature

Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.

Source: Publisher and PubMed metadata; device mentions identified by Orca1

Browse all Literature